Dionex Introduces new Acclaim Trinity Silica-based Columns for Ultimate Control of Selectivity

Dionex Corporation announces the release of a new column line: the Acclaim® Trinity™ P1 for separation of active pharmaceutical ingredients (API) and their respective counterions. The new column chemistry is based on our new innovative Nanopolymer Silica Hybrid (NSH) technology, designed for maximum flexibility in optimizing selectivity during method development.

The Acclaim Trinity P1 is a unique, high-efficiency, silica-based column ideally suited for the simultaneous separation of pharmaceutical drug substances and their counterions, and delivering unparalleled chromatographic performance for mixtures of basic, acidic, and neutral drug substances.

The NSH technology creates particles with concurrent cation-exchange, anion-exchange, and reversed-phase functionalities. The silica inner-pore area is modified with an organic layer that provides both reversed-phase and anion-exchange properties. The outer surface area is modified with cation-exchange functionality. The NSH technology ensures distinctive spatial separation of the exchange regions. The functionality is therefore unsurpassed because all retention mechanisms can function simultaneously, and can be controlled independently.

The morphology of the Acclaim Trinity P1 column provides easier, straightforward, method development. Multiple parameters can be used to optimize selectivity, including mobile phase ionic strength, pH, and organic solvent content. These optimization factors can then be used to accelerate chromatographic separations, and increase productivity.